Contribution of chitosan and its derivatives to cancer chemotherapy

Yoshinori Kato, Hiraku Onishi, Yoshiharu Machida

Research output: Contribution to journalArticle

Abstract

The conjugates of some kinds of anticancer agents with chitin and chitosan derivatives display good anticancer effects with a decrease in the adverse effects of the original drug due to a predominant distribution into the cancer and a gradual release of free drug from the conjugates. For instance, doxifluridine and 1-β-D-arabinofuranosylcytosine (Ara-C) were conjugated with chitosan via glutaric spacer, and the conjugates of Ara-C with chitosan, in particular, showed a good antitumour effect against P388-bearing leukemia model mice. Glycol-chitosan (G-Chi) was distributed mainly in the systemic circulation and the kidney after i.v. administration into normal mice, and retained long in the kidney. The therapeutic effect of the conjugates of mitomycin C (MMC) with G-Chi was not necessarily improved in comparison with that of the free drug, but toxic side-effects appeared to decrease with the conjugates. The conjugates of MMC with 6-O-carboxymethyl-chitin showed almost complete suppression of tumour growth at 10 mg eq. MMC/kg, though a lethal adverse effect was also observed. The conjugates of MMC with N-succinyl-chitosan showed good antitumour activities against various tumour models due to their predominant distribution into the tumour tissue and sustained-release characteristics, irrespective of water-insoluble and -soluble formulations. It is believed that the chitin and chitosan derivatives discussed in this review are good candidates for a polymeric drug carrier in cancer chemotherapy.

Original languageEnglish (US)
Pages (from-to)301-310
Number of pages10
JournalIn vivo (Athens, Greece)
Volume19
Issue number1
StatePublished - Jan 2005

Fingerprint

Chemotherapy
Chitosan
Mitomycin
Derivatives
Tumors
Drug Therapy
Chitin
Cytarabine
Neoplasms
Bearings (structural)
Pharmaceutical Preparations
Drug Carriers
Poisons
Leukemia P388
Antineoplastic Agents
Renal Circulation
Therapeutic Uses
Drug-Related Side Effects and Adverse Reactions
Tissue
Water

Keywords

  • 6-O-carboxymethyl-chitin
  • Anticancer agents
  • Antitumour activity
  • Biodistribution
  • Chitosan
  • Glyco-chitosan
  • N-succinyl-chitosan
  • Review

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Kato, Y., Onishi, H., & Machida, Y. (2005). Contribution of chitosan and its derivatives to cancer chemotherapy. In vivo (Athens, Greece), 19(1), 301-310.

Contribution of chitosan and its derivatives to cancer chemotherapy. / Kato, Yoshinori; Onishi, Hiraku; Machida, Yoshiharu.

In: In vivo (Athens, Greece), Vol. 19, No. 1, 01.2005, p. 301-310.

Research output: Contribution to journalArticle

Kato, Y, Onishi, H & Machida, Y 2005, 'Contribution of chitosan and its derivatives to cancer chemotherapy', In vivo (Athens, Greece), vol. 19, no. 1, pp. 301-310.
Kato, Yoshinori ; Onishi, Hiraku ; Machida, Yoshiharu. / Contribution of chitosan and its derivatives to cancer chemotherapy. In: In vivo (Athens, Greece). 2005 ; Vol. 19, No. 1. pp. 301-310.
@article{284bdf970e624035a679f6ebdbf32dc6,
title = "Contribution of chitosan and its derivatives to cancer chemotherapy",
abstract = "The conjugates of some kinds of anticancer agents with chitin and chitosan derivatives display good anticancer effects with a decrease in the adverse effects of the original drug due to a predominant distribution into the cancer and a gradual release of free drug from the conjugates. For instance, doxifluridine and 1-β-D-arabinofuranosylcytosine (Ara-C) were conjugated with chitosan via glutaric spacer, and the conjugates of Ara-C with chitosan, in particular, showed a good antitumour effect against P388-bearing leukemia model mice. Glycol-chitosan (G-Chi) was distributed mainly in the systemic circulation and the kidney after i.v. administration into normal mice, and retained long in the kidney. The therapeutic effect of the conjugates of mitomycin C (MMC) with G-Chi was not necessarily improved in comparison with that of the free drug, but toxic side-effects appeared to decrease with the conjugates. The conjugates of MMC with 6-O-carboxymethyl-chitin showed almost complete suppression of tumour growth at 10 mg eq. MMC/kg, though a lethal adverse effect was also observed. The conjugates of MMC with N-succinyl-chitosan showed good antitumour activities against various tumour models due to their predominant distribution into the tumour tissue and sustained-release characteristics, irrespective of water-insoluble and -soluble formulations. It is believed that the chitin and chitosan derivatives discussed in this review are good candidates for a polymeric drug carrier in cancer chemotherapy.",
keywords = "6-O-carboxymethyl-chitin, Anticancer agents, Antitumour activity, Biodistribution, Chitosan, Glyco-chitosan, N-succinyl-chitosan, Review",
author = "Yoshinori Kato and Hiraku Onishi and Yoshiharu Machida",
year = "2005",
month = "1",
language = "English (US)",
volume = "19",
pages = "301--310",
journal = "In Vivo",
issn = "0258-851X",
publisher = "International Institute of Anticancer Research",
number = "1",

}

TY - JOUR

T1 - Contribution of chitosan and its derivatives to cancer chemotherapy

AU - Kato, Yoshinori

AU - Onishi, Hiraku

AU - Machida, Yoshiharu

PY - 2005/1

Y1 - 2005/1

N2 - The conjugates of some kinds of anticancer agents with chitin and chitosan derivatives display good anticancer effects with a decrease in the adverse effects of the original drug due to a predominant distribution into the cancer and a gradual release of free drug from the conjugates. For instance, doxifluridine and 1-β-D-arabinofuranosylcytosine (Ara-C) were conjugated with chitosan via glutaric spacer, and the conjugates of Ara-C with chitosan, in particular, showed a good antitumour effect against P388-bearing leukemia model mice. Glycol-chitosan (G-Chi) was distributed mainly in the systemic circulation and the kidney after i.v. administration into normal mice, and retained long in the kidney. The therapeutic effect of the conjugates of mitomycin C (MMC) with G-Chi was not necessarily improved in comparison with that of the free drug, but toxic side-effects appeared to decrease with the conjugates. The conjugates of MMC with 6-O-carboxymethyl-chitin showed almost complete suppression of tumour growth at 10 mg eq. MMC/kg, though a lethal adverse effect was also observed. The conjugates of MMC with N-succinyl-chitosan showed good antitumour activities against various tumour models due to their predominant distribution into the tumour tissue and sustained-release characteristics, irrespective of water-insoluble and -soluble formulations. It is believed that the chitin and chitosan derivatives discussed in this review are good candidates for a polymeric drug carrier in cancer chemotherapy.

AB - The conjugates of some kinds of anticancer agents with chitin and chitosan derivatives display good anticancer effects with a decrease in the adverse effects of the original drug due to a predominant distribution into the cancer and a gradual release of free drug from the conjugates. For instance, doxifluridine and 1-β-D-arabinofuranosylcytosine (Ara-C) were conjugated with chitosan via glutaric spacer, and the conjugates of Ara-C with chitosan, in particular, showed a good antitumour effect against P388-bearing leukemia model mice. Glycol-chitosan (G-Chi) was distributed mainly in the systemic circulation and the kidney after i.v. administration into normal mice, and retained long in the kidney. The therapeutic effect of the conjugates of mitomycin C (MMC) with G-Chi was not necessarily improved in comparison with that of the free drug, but toxic side-effects appeared to decrease with the conjugates. The conjugates of MMC with 6-O-carboxymethyl-chitin showed almost complete suppression of tumour growth at 10 mg eq. MMC/kg, though a lethal adverse effect was also observed. The conjugates of MMC with N-succinyl-chitosan showed good antitumour activities against various tumour models due to their predominant distribution into the tumour tissue and sustained-release characteristics, irrespective of water-insoluble and -soluble formulations. It is believed that the chitin and chitosan derivatives discussed in this review are good candidates for a polymeric drug carrier in cancer chemotherapy.

KW - 6-O-carboxymethyl-chitin

KW - Anticancer agents

KW - Antitumour activity

KW - Biodistribution

KW - Chitosan

KW - Glyco-chitosan

KW - N-succinyl-chitosan

KW - Review

UR - http://www.scopus.com/inward/record.url?scp=16244400529&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=16244400529&partnerID=8YFLogxK

M3 - Article

C2 - 15796190

AN - SCOPUS:16244400529

VL - 19

SP - 301

EP - 310

JO - In Vivo

JF - In Vivo

SN - 0258-851X

IS - 1

ER -